Skip to Main content Skip to Navigation
Journal articles

Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?

Ken Ho 1 Maria Fleseriu 2 Ursula Kaiser 3 Roberto Salvatori 4 Thierry Brue 5, 6, 7 M Beatriz Lopes 8 Pamela Kunz 9 Mark Molitch 10 Sally Camper 11 Mônica Gadelha 12 Luis Syro 13 Edward Laws 3 Martin Reincke 14 Hiroshi Nishioka 15 Ashley Grossman 16 Ariel Barkan 11 Felipe Casanueva 17 John Wass 18 Adam Mamelak 19 Laurence Katznelson 20 Aart van der Lely 21 Sally Radovick 22 Martin Bidlingmaier 14 Margaret Boguszewski 23 Jens Bollerslev 24 Andrew Hoffman 25 Nelson Oyesiku 26 Gerald Raverot 27 Anat Ben-Shlomo 19 Rob Fowkes 28 Ilan Shimon 29 Hidenori Fukuoka 30 Alberto Pereira 31 Yona Greenman 32 Anthony Heaney 33 Mark Gurnell 34 Gudmundur Johannsson 35 Robert Osamura 36 Michael Buchfelder 37 Maria Chiara Zatelli 38 Marta Korbonits 39 Philippe Chanson 40 Nienke Biermasz 31 David Clemmons 41 Niki Karavitaki 42 Marcello Bronstein 43 Peter Trainer 44 Shlomo Melmed 19
1 Garvan Institute of Medical Research
2 Oregon Health & Science University
3 BWH - Brigham & Women’s Hospital [Boston]
4 JHU - Johns Hopkins University
5 MMG - Marseille medical genetics - Centre de génétique médicale de Marseille
6 MarMaRa - Institut Marseille Maladies Rares
7 Service d'endocrinologie, diabète, maladies métaboliques [Hôpital de la Conception - APHM]
8 University of Virginia [Charlottesville]
9 Yale University School of Medicine
10 Northwestern University [Evanston]
11 University of Michigan [Ann Arbor]
12 UNIRIO - Universidade Federal do Estado do Rio de Janeiro
13 Hospital Pablo Tobón Uribe [Medellín, Colombie]
14 LMU - Ludwig-Maximilians-Universität München
15 Toranomon Hospital [Tokyo, Japan]
16 University of Oxford [Oxford]
17 USC - Universidade de Santiago de Compostela [Spain]
18 Churchill Hospital [Breast Care Unit]
19 Cedars-Sinai Medical Center
20 Stanford University
21 Erasmus MC - Erasmus University Medical Center [Rotterdam]
22 Rutgers-New Brunswick - Rutgers Robert Wood Johnson Medical School [New Brunswick, NJ, USA]
23 UTFPR - Federal University of Technology - Paraná
24 UiO - University of Oslo
25 Stanford University School of Medicine [CA, USA]
26 Emory University School of Medicine
27 HCL - Hospices Civils de Lyon
28 University of London [London]
29 Beilinson Hospital
30 Kobe University Hospital
31 Leiden University Medical Center (LUMC)
32 Tel Aviv Sourasky Medical Center [Te Aviv]
33 UCLA - University of California [Los Angeles]
34 CAM - University of Cambridge [UK]
35 GU - University of Gothenburg
36 Keio University School of Medicine [Tokyo, Japan]
37 Erlangen University Hospital
38 University of Ferrara [Ferrara]
39 QMUL - Queen Mary University of London
40 Université Paris-Saclay
41 University of North Carolina at Chapel Hill School of Medicine
42 University of Birmingham [Birmingham]
43 Universidade Federal de São Paulo
44 University of Manchester [Manchester]
Abstract : Abstract The WHO Classification of Endocrine Tumours designates pituitary neoplasms as adenomas. A proposed nomenclature change to pituitary neuroendocrine tumors (PitNETs) has been met with concern by some stakeholder groups. The Pituitary Society coordinated the Pituitary Neoplasm Nomenclature (PANOMEN) workshop to address the topic. Experts in pituitary developmental biology, pathology, neurosurgery, endocrinology, and oncology, including representatives nominated by the Endocrine Society, European Society of Endocrinology, European Neuroendocrine Association, Growth Hormone Research Society, and International Society of Pituitary Surgeons. Clinical epidemiology, disease phenotype, management, and prognosis of pituitary adenomas differ from that of most NETs. The vast majority of pituitary adenomas are benign and do not adversely impact life expectancy. A nomenclature change to PitNET does not address the main challenge of prognostic prediction, assigns an uncertain malignancy designation to benign pituitary adenomas, and may adversely affect patients. Due to pandemic restrictions, the workshop was conducted virtually, with audiovisual lectures and written précis on each topic provided to all participants. Feedback was collated and summarized by Content Chairs and discussed during a virtual writing meeting moderated by Session Chairs, which yielded an evidence-based draft document sent to all participants for review and approval. There is not yet a case for adopting the PitNET nomenclature. The PANOMEN Workshop recommends that the term adenoma be retained and that the topic be revisited as new evidence on pituitary neoplasm biology emerges.
Keywords : neuroendocrine tumor pituitary adenoma Pituitary neoplasm
Document type :
Journal articles
Complete list of metadata
https://hal-amu.archives-ouvertes.fr/hal-03310331
Contributor : Valérie Gall Connect in order to contact the contributor
Submitted on : Friday, July 30, 2021 - 1:09:39 PM
Last modification on : Tuesday, October 19, 2021 - 10:51:00 PM
Long-term archiving on: : Sunday, October 31, 2021 - 6:16:05 PM

File

Vignette du document
Ho 2021 J Endocr Soc_PANOMEN a...
Publisher files allowed on an open archive

Licence

Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

Identifiers

Collections

UNIV-AMU | HCL | MMG | MARMARA | INSERM

Citation

Ken Ho, Maria Fleseriu, Ursula Kaiser, Roberto Salvatori, Thierry Brue, et al.. Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. Journal of the Endocrine Society, Oxford University Press, 2021, 5 (3), ⟨10.1210/jendso/bvaa205⟩. ⟨hal-03310331⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

36

Files downloads

47